Aberrant Expressions of AP-2α Splice Variants in Pancreatic Cancer
- 1 July 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Pancreas
- Vol. 40 (5), 695-700
- https://doi.org/10.1097/mpa.0b013e31821f2715
Abstract
Objectives: The present study was conducted to evaluate the expression and function of AP-2α isoforms in pancreatic ductal adenocarcinoma. Methods: The expression of AP-2α was evaluated at the RNA level by reverse transcription-polymerase chain reaction and at the protein level by Western blotting and immunofluorescence. Its function as a transcription factor was evaluated in transient transfection experiments: DNA binding properties by electromobility shift assay and transactivation capabilities by luciferase assay. Results: Multiple alternative splicing events of AP-2α messenger occurred in all human pancreatic cancer cell lines, including a novel isoform, termed variant 6, which was not present in HeLa cells. At the protein level, except for 1 cell line, all pancreatic cancer cell lines expressed high nuclear levels of AP-2α. We also showed that AP-2α expressed by the pancreatic cancer cell lines could bind its cognate recognition site and activate transcription. However, variant 6, although not able to activate transcription, did not act in a dominant negative manner when cotransfected with the full-length protein. Conclusions: Multiple isoforms of AP-2α are highly expressed in pancreatic cancer cell lines including a new isoform, AP-2α variant 6, which seems to be pancreatic cancer specific and is deprived of transcriptional activity.Keywords
This publication has 45 references indexed in Scilit:
- AP-2Inhibits c-MYC Induced Oxidative Stress and Apoptosis in HaCaT Human KeratinocytesJournal of Oncology, 2009
- Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplificationBreast Cancer Research, 2009
- Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2α overexpressionBritish Journal of Cancer, 2009
- Sp1, a New Biomarker That Identifies a Subset of Aggressive Pancreatic Ductal AdenocarcinomaCancer Epidemiology, Biomarkers & Prevention, 2008
- Id family of helix-loop-helix proteins in cancerNature Reviews Cancer, 2005
- Loss of AP-2α impacts multiple aspects of ventral body wall development and closureDevelopmental Biology, 2004
- Activator Protein 2α Inhibits Tumorigenicity and Represses Vascular Endothelial Growth Factor Transcription in Prostate Cancer CellsCancer Research, 2004
- Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancerThe Journal of Pathology, 1999
- AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expressionNature Genetics, 1997
- Pancreatic CarcinomaThe New England Journal of Medicine, 1992